Part A reached a predefined stopping criteria. Relevant doses for part B could not be established based on A and subsequently study was stopped.

The purpose of this study is to assess safety and tolerability of AZD6714 after single ascending oral doses in healthy male subjects and type 2 diabetic patients.

Inclusion Criteria:

• Part A,Healthy male subjects, aged between ≥20 and ≤40 years.
• Part B,Male T2DM patients, aged between ≥20 and ≤65 years. Treatment with metformin as single therapy for T2DM for at least 30 days prior to enrollment

Exclusion Criteria:

• Part A,Clin sign illness or clin relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the IP.
• Part A Clin sign abnormalities in clinical chemistry, haematology, or urinalysis results as judged by the investigator
• Part B, History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease.
• Any clinically significant abnormality identified on physical examination, laboratory tests or ECG, which in the judgment of the investigator would compromise the patient's safety or successful participation.